Streetbeat News

Products Services

AIMD

Ainos has submitted a complete response to the US FDA to address deficiencies in its Investigational New Drug (IND) application for a Phase II trial of VELDONA, aimed at treating mild COVID-19 symptoms. This step is crucial for advancing the drug's development and potentially bringing a new treatment option to market.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:05 pm

AZN

Yiviva and AstraZeneca China have signed an MOU to collaborate on developing systems biology medicines at AstraZeneca's iCampus in Chengdu, China. This partnership aims to modernize botanical medicines and address global medical needs by integrating traditional Chinese and Western medicine. Yiviva's STAR platform has discovered six drug candidates, with YIV-906 showing promise in early-stage clinical trials for various cancers. The collaboration was announced at the 2023 CIIE, marking AstraZeneca's 30th anniversary in China.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:04 pm

SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced it will present clinical efficacy data for neffy, an epinephrine nasal spray, at the 2024 AAAAI meeting. The data includes 100% response rate in pediatric anaphylaxis cases from oral food challenges and significant reductions in urticaria symptoms. The company is on track to report topline results from a repeat dose study in Q1 2024, with an NDA re-submission expected in mid-H1 2024. The presentations aim to support post-marketing promotion of neffy, pending approval.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:02 pm

COGT

Cogent Biosciences announced it will present Part 1b data of its drug Bezuclastinib for treating non-advanced systemic mastocytosis at the 2024 AAAAI Annual Meeting. This could indicate positive progress in the drug's development.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:01 pm

AAPL

TSLA

A Tesla Inc. (TSLA) driver was pulled over for driving while wearing Apple Inc.'s (AAPL) new mixed reality headset, Apple Vision Pro. The incident has sparked a debate on social media, with some users calling for the driver's arrest for endangering road safety. The Apple Vision Pro's launch has led to various innovative and controversial uses, highlighting its potential and the risks of misuse.

Portfolio Pulse from Rounak Jain

February 05, 2024 | 1:59 pm

AAPL

NVDA

Huawei Technologies Co has shifted its focus towards AI, impacting its Mate 60 smartphone production, to compete with Nvidia Corp's AI chips, particularly in the Chinese market. Nvidia has launched the H20 AI chip, priced between $12,000 and $15,000, to compete with Huawei's 910B chip. The U.S. has tightened AI chip sales to China, prompting a shift towards domestic options like Huawei's Ascend series. Despite challenges, Huawei leads Chinese smartphone sales, and Nvidia's shares rose by 3.07% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 05, 2024 | 1:58 pm

TSM

TSMC, a leading semiconductor manufacturer, has reportedly not placed orders for high-numerical aperture (High-NA) extreme ultraviolet (EUV) tools. Sources from fab toolmakers suggest that TSMC is unlikely to use this technology for its upcoming 2nm and 1.4nm (A14) process manufacturing.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:58 pm

AAPL

According to DigiTimes Alerts, sources indicate that Chinese suppliers dominate a significant portion of the supply chain for Vision Pro, a product associated with Apple Inc. (AAPL). This information highlights the reliance of major tech companies on Chinese manufacturing and supply networks.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:58 pm

AAPL

DigiTimes Alerts has reported that a new iPad is expected to debut in March, according to recent market speculations. This news could potentially impact Apple Inc.'s stock as investors anticipate the release of the new product.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:57 pm

VALN

Valneva SE (NASDAQ:VALN) sold an FDA Priority Review Voucher for $103 million, awarded for the approval of Ixchiq, the first licensed chikungunya vaccine. The proceeds will fund R&D, including Phase 3 Lyme disease vaccine trials and further chikungunya vaccine trials. Valneva reported positive 24-month antibody persistence data for Ixchiq. The global market for chikungunya vaccines is expected to exceed $500 million annually by 2032. VALN shares are down 1.11% in premarket trading.

Portfolio Pulse from Vandana Singh

February 05, 2024 | 1:55 pm